ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...

Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

Adjuvant BCG therapy of superficial bladder cancer remains the most successful immunotherapy for human malignancies and surpasses the efficacy of intravesical chemotherapy. Importantly ...

UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors ...

Nadofaragene firadenovec appears effective in real-world patients with bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...

Eligibility criteria include histologically confirmed high-grade cT1N0M0 bladder cancer meeting cystectomy criteria off-trial and one of the following: Recurrent high-grade T1 disease after TURBT + at ...